Cited by 185Protein Kinase Regulation and GTPase SignalingPI3K/AKT/mTOR signaling in cancerSignaling Pathways in Disease

The DOI matches its Crossref record; 108 of the 109 references it cites were found in a registry or an index.

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

Kortmansky, Jeremy, Schwartz, Gary K.·2003·Cancer Investigation

DOI 10.1081/cnv-120025095

Open this paper in CoChat — free account

Abstract

Modulation of PKC represents a novel approach to cancer therapy. Bryostatin-1 is a macrocyclic lactone derived from a marine invertebrate that binds to the regulatory domain of protein kinase C. Short-term exposure to bryostatin-1 promotes activation of PKC, whereas prolonged exposure promotes significant downregulation of PKC. In numerous hematological and solid tumor cell lines, bryostatin-1 inhibits proliferation, induces differentiation, and promotes apoptosis. Furthermore, preclinical studies indicate that bryostatin-1 potently enhances the effect of chemotherapy. In many cases, this effect is sequence specific. Bryostatin-1 is currently in phase I and phase II clinical trials. The major toxicities are myalgias, nausea, and vomiting. Although there is minimal single-agent activity, combinations with standard chemotherapy are providing very encouraging results and indicate a new direction in cancer therapy.

Integrity signals

Registry

Crossref · 10.1081/cnv-120025095

Cites

108 of 108 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The extended protein kinase C superfamily
MELLOR, H., & Parker, P. J. (1998) · Biochemical Journal · doi:10.1042/bj3320281 · Cited by 1,539
Matrix metalloproteinase inhibitors
Wojtowicz‐Praga, S., Dickson, R. B., & Hawkins, M. (1997) · Investigational New Drugs · doi:10.1023/a:1005722729132 · Cited by 524
Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma
Moch, H., Gasser, T., Amin, M. B., Torhorst, J. K. H., Sauter, G., & Mihatsch, M. J. (2000) · Cancer · doi:10.1002/1097-0142(20000801)89:3 · Cited by 472
A Functional Role for Mitochondrial Protein Kinase Cα in Bcl2 Phosphorylation and Suppression of Apoptosis
Ruvolo, P. P., Deng, X., Carr, B. K., & May, W. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.39.25436 · Cited by 452
Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60.
Kraft, A. S., Smith, J. B., & Berkow, R. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.5.1334 · Cited by 257
Selective translocation of beta II-protein kinase C to the nucleus of human promyelocytic (HL60) leukemia cells.
Hocevar, B. A., & Fields, A. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52396-6 · Cited by 248
Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin
Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R., & Yuspa, S. H. (1987) · Carcinogenesis · doi:10.1093/carcin/8.9.1343 · Cited by 230
Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis.
May, W. S., Tyler, P. G., Ito, T., Armstrong, D. K., Qatsha, K. A., & Davidson, N. E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47099-8 · Cited by 219
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.
Wender, P. A., CRIBBS, C. M., Koehler, K. F., Sharkey, N. A., Herald, C. L., Kamano, Y., Pettit, G. R., & Blumberg, P. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7197 · Cited by 201
Bryostatin and CD40‐ligand enhance apoptosis resistance and induce expression of cell survival genes in B‐cell chronic lymphocytic leukaemia
Kitada, S., Zapata, J. M., Andreeff, M., & Reed, J. C. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01642.x · Cited by 187
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor Induction In Vivo
Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S. A., Rockett, H. R. H., Talbot, D., Ganesan, T. S., Pettit, G. R., Balkwill, F. R., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.22.1812 · Cited by 187
Chemistry and clinical biology of the bryostatins
Mutter, R., & Wills, M. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00150-4 · Cited by 178
1-beta-D-Arabinofuranosylcytosine stimulates ceramide and diglyceride formation in HL-60 cells.
Strum, J. C., Small, G. W., Pauig, S. B., & Daniel, L. W. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40706-x · Cited by 163
Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C.
Fields, A. P., Pettit, G. R., & May, W. S. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)68471-6 · Cited by 163
Ubiquitination of Protein Kinase C-α and Degradation by the Proteasome
Lee, H., Smith, L., Pettit, G. R., Vinitsky, A., & Smith, J. B. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.35.20973 · Cited by 163
A phase I study of intravenous bryostatin 1 in patients with advanced cancer
Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A. T., Testa, N. G., Stern, P. L., McDermott, R. H., Potter, M., et al. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.352 · Cited by 145
Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
Hornung, R. L., Pearson, J. W., Beckwith, M., & Longo, D. L. (1992) · PubMed · Cited by 134
Protein Kinase C (PKC) Inhibits Fas Receptor-induced Apoptosis through Modulation of the Loss of K+ and Cell Shrinkage
Gómez-Angelats, M., Bortner, C. D., & Cidlowski, J. A. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m909563199 · Cited by 125
A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P. L., Young, R., Brenchley, P. E., Chang, J., Owens, S. E., et al. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.356 · Cited by 125
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian, M. L., Mohammad, R. M., Eilender, D., Hulburd, K., Rodriguez, D. H., Pemberton, P. A., Pluda, J. M., Dan, M., Pettit, G. R., Chen, B. D. M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.56 · Cited by 114
Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines.
Kennedy, M. J., Prestigiacomo, L. J., Tyler, G., May, W. S., & Davidson, N. E. (1992) · PubMed · Cited by 105
Bryostatin 1, a unique biologic response modifier: anti-leukemic activity in vitro
Jones, R., Sharkis, S. J., Miller, C., Rowinsky, E. K., Burke, P., & May, W. S. (1990) · Blood · doi:10.1182/blood.v75.6.1319.bloodjournal7561319 · Cited by 98
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian, M. L., Mohammad, R. M., Shurafa, M. S., Hulburd, K., Pemberton, P., Rodriguez, D. H., Spadoni, V., Eilender, D. S., Murgo, A. J., Wall, N. R., et al. (2000) · PubMed · Cited by 97
Successful treatment of murine melanoma with bryostatin 1.
Schuchter, L. M., Esa, A. H., May, W. S., Laulis, M. K., Pettit, G. R., & Hess, A. D. (1991) · PubMed · Cited by 94
Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C
Isakov, N., Galron, D., Mustelin, T., Pettit, G. R., & Altman, A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.150.4.1195 · Cited by 92
Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-d-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells
Jarvis, W. D., Povirk, L. F., Turner, A., Traylor, R. S., Gewirtz, D. A., Pettit, G. R., & Grant, S. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90484-7 · Cited by 85
Protein Kinase C Targeting in Antineoplastic Treatment Strategies
Jarvis, W. D., & Grant, S. (1999) · Investigational New Drugs · doi:10.1023/a:1006328303451 · Cited by 84
A phase II study of bryostatin 1 in metastatic malignant melanoma
Propper, D., Macaulay, V. M., O'Byrne, K. J., Braybrooke, J. P., Wilner, S., Ganesan, T., Talbot, D., & Harris, A. L. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.680 · Cited by 83
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder, J. A., Shields, A. F., Zalupski, M. M., Chaplen, R., Heilbrun, L. K., Arlauskas, P., & Philip, P. A. (2001) · PubMed · Cited by 82
Regulation of Caspase Activation and cis-Diamminedichloroplatinum(II)-Induced Cell Death by Protein Kinase C
Basu, A., & Akkaraju, G. R. (1999) · Biochemistry · doi:10.1021/bi982854q · Cited by 80
Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.
Trenn, G., Pettit, G. R., Takayama, H., Hu‐Li, J., & Sitkovsky, M. V. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.2.433 · Cited by 78
Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2.
Asiedu, C. K., Biggs, J. R., Lilly, M. B., & Kraft, A. S. (1995) · PubMed · Cited by 74
Activation of human T lymphocytes by bryostatin.
Hess, A. D., Silanskis, M., Esa, A. H., Pettit, G. R., & May, W. S. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.10.3263 · Cited by 70
Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain
Vries, D. J. D., Herald, C. L., Pettit, G. R., & Blumberg, P. M. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90097-4 · Cited by 69
A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma
Blackhall, F. H., Ranson, M., Radford, J. A., Hancock, B. W., Soukop, M., McGown, A. T., Robbins, A. K., & Halbert, G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1624 · Cited by 68
The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad, R. M., Wall, N. R., Dutcher, J. A., & Al-Katib, A. M. (2000) · PubMed · Cited by 66
Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60).
Kraft, A. S., Vv, B., & Ws, M. (1987) · PubMed · Cited by 66
Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts.
Al-Katib, A. M., Smith, M. R., Kamanda, W. S., Pettit, G. R., Hamdan, M., Mohamed, A. N., Chelladurai, B. S., & Mohammad, R. M. (1998) · PubMed · Cited by 65
gamma-Interferon plays a key role in T-cell-induced tumor regression.
Tuttle, T. M., McCrady, C. W., Inge, T. H., Salour, M., & Bear, H. D. (1993) · PubMed · Cited by 64
Effect of bryostatin 1 on taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937)
Wang, S., Guo, C., Castillo, A., Dent, P., & Grant, S. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00188-9 · Cited by 63
Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells
Drexler, H. G., Gignac, S. M., Jones, R., Cs, S., Pettit, G., & Hoffbrand, A. V. (1989) · Blood · doi:10.1182/blood.v74.5.1747.bloodjournal7451747 · Cited by 63
Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937)
Vrana, J. A., Saunders, A. M., Chellappan, S., & Grant, S. (1998) · Differentiation · doi:10.1046/j.1432-0436.1998.6310033.x · Cited by 62
The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF‐7 breast carcinoma cells
Tanwell, C. S., Gescher, A. J., Bradshaw, T. D., & Pettit, G. R. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560420 · Cited by 62
Regulation of Motility and Protease Expression in PKC-Mediated Induction of MCF-7 Breast Cancer Cell Invasiveness
Johnson, M. D., Torri, J. A., Lippman, M. E., & Dickson, R. B. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4336 · Cited by 62
The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher, J. A., Motwani, M., Zakian, K. L., Li, X. K., Matei, C., Dyke, J. P., Ballon, D., Yoo, H. H., & Schwartz, G. K. (2000) · PubMed · Cited by 60
Self-citation
Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells
Dale, I. L., & Gescher, A. J. (1989) · International Journal of Cancer · doi:10.1002/ijc.2910430129 · Cited by 59
Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle, T. M., Inge, T. H., Bethke, K. P., McCrady, C. W., Pettit, G. R., & Bear, H. D. (1992) · PubMed · Cited by 56
Evidence for Protein Kinase C-Dependent and -Independent Activation of Mitogen-Activated Protein Kinase in T Cells: Potential Role of Additional Diacylglycerol Binding Proteins
Puente, L. G., Stone, J. C., & Ostergaard, H. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6865 · Cited by 54
Bryostatin 1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma
Mohammad, R. M., Diwakaran, H., Maki, A., Emara, A. M., Pettit, G. R., Redman, B. G., & Al-Katib, A. M. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00037-o · Cited by 53
The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szállási, Z., Du, L., Levine, R., Lewin, N. E., Nguyen, P. N., Williams, M. D., Pettit, G. R., & Blumberg, P. M. (1996) · PubMed · Cited by 51
Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant, S., Roberts, J. D., Poplin, E. A., Tombes, M. B., Kyle, B., Welch, D. G., Carr, M. A., & Bear, H. D. (1998) · PubMed · Cited by 51
Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL
Wang, S., Wang, Z., Boise, L., Dent, P., & Grant, S. (1999) · Leukemia · doi:10.1038/sj.leu.2401532 · Cited by 51
Successful treatment of human Waldenström's macroglobulinemia with combination biological and chemotherapy agents.
Mohammad, R. M., Al-Katib, A. M., Pettit, G. R., & Sensenbrenner, L. (1994) · PubMed · Cited by 48
In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow, R. L., Schlabach, L., Dodson, R., Benjamin, W. H., Pettit, G. R., Rustagi, P. K., & Kraft, A. S. (1993) · PubMed · Cited by 45
Treatment of patients with metastatic melanoma with bryostatin-1 - phase II study
González, R., Ebbinghaus, S., Henthorn, T. K., Miller, D. M., & Kraft, A. S. (1999) · Melanoma Research · doi:10.1097/00008390-199912000-00010 · Cited by 45
Bryostatin 1 induces prolonged activation of extracellular regulated protein kinases in and apoptosis of LNCaP human prostate cancer cells overexpressing protein kinase calpha.
Gschwend, J. E., Fair, W. R., & Powell, C. T. (2000) · PubMed · Cited by 43
Bryostatin 1-induced hairy cell features on chronic lymphocytic leukemia cells in vitro.
Al-Katib, A. M., Mohammad, R. M., Dan, M., Hussein, M. E., Akhtar, A. J., Pettit, G. R., & Sensenbrenner, L. (1993) · PubMed · Cited by 43
Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad, R. M., Varterasian, M. L., Almatchy, V. P., Hannoudi, G. N., Pettit, G. R., & Al-Katib, A. M. (1998) · PubMed · Cited by 41
Modulation of gene expression in the acute promyelocytic leukemia cell line NB4.
Hu, Z., Ma, W., Uphoff, C. C., Lanotte, M., & Drexler, H. G. (1993) · PubMed · Cited by 41
Establishment of a Human Pancreatic Tumor Xenograft Model
Mohammad, R. M., Dugan, M. C., Mohamed, A. N., Almatchy, V. P., Flake, T. M., Dergham, S. T., Shields, A. F., Al-Katib, A., Vaitkevicius, V. K., & Sarkar, F. H. (1998) · Pancreas · doi:10.1097/00006676-199801000-00004 · Cited by 40
Phase II evaluation of bryostatin-1 in metastatic melanoma
Bedikian, A. Y., Plager, C., Stewart, J. R., O'Brian, C. A., Herdman, S., Ross, M., Papadopoulos, N., Eton, O. E., Ellerhorst, J. A., & Smith, T. (2001) · Melanoma Research · doi:10.1097/00008390-200104000-00014 · Cited by 40
Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line
Liu, K. Z., Schultz, C., Johnston, J., Beck, F. J., al-Katib, A., Rm, M., & Mantsch, H. H. (1999) · Leukemia · doi:10.1038/sj.leu.2401463 · Cited by 37
c-kit expression in human megakaryoblastic leukemia cell lines
Hu, Z., Ma, W., Uphoff, C., Quentmeier, H., & Drexler, H. G. (1994) · Blood · doi:10.1182/blood.v83.8.2133.2133 · Cited by 37
Mitogen-activated Protein Kinase Is Involved in the Degradation of p53 Protein in the Bryostatin-1-induced Differentiation of the Acute Promyelocytic Leukemia NB4 Cell Line
Song, X., Sheppard, H. M., Norman, A. W., & Liu, X. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.3.1677 · Cited by 36
A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman, S. D., Langevin, A., Berkow, R. L., Thomas, P. J., Hurwitz, C. A., Kraft, A. S., Dubowy, R. L., Smith, D. L., & Bernstein, M. L. (1999) · PubMed · Cited by 35
Bryostatin 1, a novel antineoplastic agent and protein kinase C activator, induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study
Hickman, P. H., Kemp, G. J., Thompson, C., Salisbury, A., Wade, K., Harris, A. L., & Radda, G. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.449 · Cited by 35
Comparison of the antitumor activity of bryostatins 1, 5, and 8
Kraft, A. S., Woodley, S., Pettit, G. R., Gao, F., Coll, J. C., & Wagner, F. H. (1995) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00688328 · Cited by 35
p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity.
Wang, H., Mohammad, R. M., Werdell, J., & Shekhar, M. P. V. (1998) · International Journal of Molecular Medicine · doi:10.3892/ijmm.1.6.915 · Cited by 35
The Antineoplastic Agent Bryostatin-1 Induces Proinflammatory Cytokine Production in Human Monocytes: Synergy With Interleukin-2 and Modulation of Interleukin-2Rγ Chain Expression
Bosco, M. C., Rottschafer, S., Taylor, L. S., Ortaldo, J. R., Longo, D. L., & Espinoza‐Delgado, I. (1997) · Blood · doi:10.1182/blood.v89.9.3402 · Cited by 34
Potentiation of 2-Chlorodeoxyadenosine Activity by Bryostatin 1 in the Resistant Chronic Lymphocytic Leukemia Cell Line (WSU-CLL): Association with Increased Ratios of dCK/5'-NT and Bax/Bcl-2
Mohammad, R. M., Beck, F. W. J., Katato, K., Hamdy, N., Wall, N. R., & Al-Katib, A. (1998) · Biological Chemistry · doi:10.1515/bchm.1998.379.10.1253 · Cited by 32
Phase II Studies of Bryostatin-1 in Patients with Advanced Sarcoma and Advanced Head and Neck Cancer
Brockstein, B., Samuels, B. L., Humerickhouse, R. A., Arrieta, R. L., Fishkin, P. A. S., Wade, J., Sosman, J. A., & Vokes, E. E. (2001) · Investigational New Drugs · doi:10.1023/a:1010628903248 · Cited by 31
Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia.
Lilly, M., Brown, C., Pettit, G. R., & Kraft, A. S. (1991) · PubMed · Cited by 30
Induction of apoptosis and differentiation by fludarabine in human leukemia cells (U937): interactions with the macrocyclic lactone bryostatin 1
Vrana, J. A., Wang, Z., Rao, A. S., Tang, L., Chen, J.-H., Kramer, L., & Grant, S. (1999) · Leukemia · doi:10.1038/sj.leu.2401454 · Cited by 29
Proteolytic cleavage of protein kinase Cμ upon induction of apoptosis in U937 cells
Häußermann, S., Kittstein, W., Rincke, G., Johannes, F., Marks, F., & Gschwendt, M. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01577-x · Cited by 28
Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.
Wall, N. R., Mohammad, R. M., Reddy, K. B., & Al-Katib, A. M. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.5.2.165 · Cited by 28
Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin.
Lilly, M., Tompkins, C., Brown, C., Pettit, G. R., & Kraft, A. S. (1990) · PubMed · Cited by 26
Overexpression of novel protein kinase C δ in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo
Porta, C. A. M. L., Dio, A. D., Porro, D., & Comolli, R. (2000) · Melanoma Research · doi:10.1097/00008390-200010020-00001 · Cited by 26
Modulation of resistance to ara-C by bryostatin in fresh blast cells from patients with AML
Elgie, A. W., Sargent, J. M., Alton, P., Peters, G. J., Noordhuis, P., Williamson, C. J., & Taylor, C. G. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00011-3 · Cited by 25
Bryostatin 1-Induced Modulation of the Acute Lymphoblastic Leukemia Cell Line Reh
Al-Katib, A., Mohammad, R. M., Khan, K. M., Dan, M. E., Pettit, G. R., & Sensenbrenner, L. (1993) · Journal of Immunotherapy · doi:10.1097/00002371-199307000-00005 · Cited by 25
Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala, S., Dickstein, B., Regis, J. T., Szállási, Z., Blumberg, P. M., & Bates, S. E. (1995) · PubMed · Cited by 24
Bryostatin 1-activated T cells can traffic and mediate tumor regression
Tuttle, T. M., Bethke, K. P., Inge, T. H., McCrady, C. W., Pettit, G. R., & Bear, H. D. (1992) · Journal of Surgical Research · doi:10.1016/0022-4804(92)90126-k · Cited by 23
Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients
Lind, D. S., Tuttle, T. M., Bethke, K. P., Frank, J. L., McCrady, C. W., & Bear, H. D. (1993) · Surgical Oncology · doi:10.1016/s0960-7404(06)80002-2 · Cited by 23
Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells
Vrana, J. A., Kramer, L. B., Saunders, A. M., Zhang, X.-F., Dent, P., Povirk, L. F., & Grant, S. (1999) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00077-5 · Cited by 22
Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors
Li, Y., Mohammad, R. M., Al-Katib, A. M., Varterasian, M. L., & Chen, B. (1997) · Leukemia Research · doi:10.1016/s0145-2126(96)00078-1 · Cited by 22
Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes
Baldwin, N. G., Rice, C. D., Tuttle, T. M., Bear, H. D., Hirsch, J. I., & Merchant, R. E. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005719700570 · Cited by 20
Bryostatin 1 Activates T Cells That Have Antitumor Activity
Tuttle, T. M., Inge, T. H., Wirt, C. P., Frank, J. L., McCrady, C. W., & Bear, H. D. (1992) · Journal of Immunotherapy · doi:10.1097/00002371-199208000-00001 · Cited by 20
In vitro effects of bryostatin 1 on the metabolism and cytotoxicity of 1-β-d-arabinofuranosylcytosine in human leukemia cells
Grant, S., Boise, L., Westin, E. H., Howe, C. W. S., Pettit, G. R., Turner, A., & McCrady, C. W. (1991) · Biochemical Pharmacology · doi:10.1016/0006-2952(91)90046-8 · Cited by 19
Bryostatin 1-tamoxifen combinations show synergistic effects on the inhibition of growth of P388 cells in vitro
McGown, A. T., Jayson, G. C., Pettit, G., Haran, M. S., Ward, T. H., & Crowther, D. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.36 · Cited by 19
Phorbol esters activate proteoglycan metabolism in human colon cancer cells en route to terminal differentiation.
McBain, J. A., Pettit, G. R., & Mueller, G. C. (1990) · PubMed · Cited by 18
Conversion of high grade lymphoma tumor cell line to intermediate grade with tpa and bryostatin 1 as determined by polypeptide analysis on 2D gel electrophoresis
Al-Katib, A. M., Mohammad, R. M., Mohamed, A. N., Pettit, G. R., & Sensenbrenner, L. (1990) · Hematological Oncology · doi:10.1002/hon.2900080203 · Cited by 17
Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad, R. M., Limvarapuss, C., Hamdy, N., Dutcher, B. S., Beck, F. W., Wall, N. R., & Al-Katib, A. M. (1999) · International Journal of Oncology · doi:10.3892/ijo.14.5.945 · Cited by 15
Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: a pilot clinical trial
Bear, H. D., Roberts, J. D., Cornell, D. L., Tombes, M. B., & Kyle, B. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/s002620100199 · Cited by 14
Bryostatin/Ionomycin-Activated T Cells Mediate Regression of Established Tumors
Chin, C. S., Graham, L., Hamad, G. G., George, K. R., & Bear, H. D. (2001) · Journal of Surgical Research · doi:10.1006/jsre.2001.6181 · Cited by 14
Adoptive transfer of bryostatin 1-activated T cells provides long-term protection from tumour metastases
Tuttle, T. M., Inge, T. H., Lind, D. S., & Bear, H. D. (1992) · Surgical Oncology · doi:10.1016/0960-7404(92)90091-x · Cited by 14
Adoptive Transfer of Bryostatin-Activated Tumor-Sensitized Lymphocytes Prevents or Destroys Tumor Metastases Without Expansion In Vitro
Fleming, M. D., Bear, H. D., Lipshy, K. A., Kostuchenko, P. J., Portocarero, D., McFadden, A. W., & Barrett, S. K. (1995) · Journal of Immunotherapy · doi:10.1097/00002371-199510000-00002 · Cited by 13
Compatibility and stability of bryostatin 1 in infusion devices
Cheung, A. P., Hallock, Y. F., Vishnuvajjala, B. R., Nguyenle, T., & Wang, E. (1998) · Investigational New Drugs · doi:10.1023/a:1006187710029 · Cited by 12
Induced Expression of Alpha-Enolase in Differentiated Diffuse Large Cell Lymphoma
Mohammad, R. M., Hamdan, M. Y., Maki, A., & Al-Katib, A. (2017) · Enzyme and Protein · doi:10.1159/000474967 · Cited by 11
Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes
Rice, C. D., Baldwin, N. G., Biron, R. T., Bear, H. D., & Merchant, R. E. (1997) · Journal of Neuro-Oncology · doi:10.1023/a:1005771717409 · Cited by 11
Biological activity of 26-succinylbryostatin 1
Bignami, G. S., Wagner, F. H., Grothaus, P. G., Rustagi, P. K., Davis, D. E., & Kraft, A. S. (1996) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/0167-4889(96)00018-3 · Cited by 11
Effects of bryostatin 1 and rGM‐CSF on the metabolism of 1‐β‐ d ‐arabinofuranosylcytosine in human leukaemic myeloblasts
Grant, S., Jarvis, W. D., Turner, A., Wallace, H., & Pettit, G. R. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb06462.x · Cited by 11
Bryostatin 1 Induces Ubiquitin COOH-Terminal Hydrolase in Acute Lymphoblastic Leukemia Cells
Mohammad, R. M., Maki, A., Pettit, G. R., & Al-Katib, A. M. (2017) · Enzyme and Protein · doi:10.1159/000468636 · Cited by 11
Modulation of cIAP-1 by Novel Antitubulin Agents When Combined with Bryostatin 1 Results in Increased Apoptosis in the Human Early Pre-B Acute Lymphoblastic Leukemia Cell Line Reh
Wall, N. R., Mohammad, R. M., Nabha, S. M., Pettit, G. R., & Al-Katib, A. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1768 · Cited by 10
Chronic exposure to bryostatin-1 increases the radiosensitivity of U937 leukaemia cells ectopically expressing Bcl-2 through a non-apoptotic mechanism
Cartee, C. D. L. (2000) · International Journal of Radiation Biology · doi:10.1080/09553000050151592 · Cited by 10
The inhibitory effects of bryostatin 1 administration on the growth of rabbit papillomas
Bodily, J. M., Hoopes, D. J., Roeder, B. L., Gilbert, S. G., Pettit, G. R., Herald, C. L., Rollins, D. N., & Robison, R. A. (1999) · Cancer Letters · doi:10.1016/s0304-3835(98)00310-3 · Cited by 9
Bryostatin-5 stimulates normal human hematopoiesis and inhibits proliferation of HL60 leukemic cells
Hem, K. G. V. D., Dräger, A. M., Odding, J. H., LANGENHUIJSEN, M. M. A. C., & Huijgens, P. C. (1995) · Leukemia Research · doi:10.1016/0145-2126(94)00118-t · Cited by 8
Protective role of IL-2 during activation of T cells with bryostatin 1
Kos, F. J., Cornell, D. L., Lipke, A. B., Graham, L., & Bear, H. D. (2000) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(00)00027-8 · Cited by 8
Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
Beck, F. W., Al-Katib, A. M., Ahmad, I., Wall, N. R., Liu, K. Z., Mantsch, H. H., & Mohammad, R. M. (2000) · International Journal of Molecular Medicine · doi:10.3892/ijmm.5.4.341 · Cited by 7
Effects of bryostatin-5 and hematopoietic growth factors on acute myeloid leukemia cell differentiation, proliferation, and primary plating efficiency
Hem, K. G. V. D., Dräger, A. M., Odding, J. H., & Huijgens, P. C. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00052-p · Cited by 5

Research works printed but not linked: 43

Hu Z. B., 1993, Leukemia, 7, 1817
Lilly M., 1990, Cancer Res., 50, 5520
al-Katib A., 1993, Exp. Hematol., 21, 61
Kraft A. S., 1987, Oncogene, 1, 111
Drexler H. G., 1989, Blood, 74, 1747, 10.1182/blood.V74.5.1747.1747 · DOI
Wall N. R., 2000, Int. J. Mol. Med., 5, 165
Wang H., 1998, Int. J. Mol. Med., 1, 915
Gschwend J. E., 2000, Mol. Pharmacol., 57, 1224
Asiedu C., 1995, Cancer Res., 55, 3716
Koutcher J. A., 2000, Clin. Cancer Res., 6, 1498
Al-Katib A. M., 1998, Clin. Cancer Res., 4, 1305
Scala S., 1995, Clin. Cancer Res., 1, 1581
Lilly M., 1991, Leukemia, 5, 283
Berkow R. L., 1993, Cancer Res., 53, 2810
Szallasi Z., 1996, Cancer Res., 56, 2105
Schuchter L. M., 1991, Cancer Res., 51, 682
Hornung R. L., 1992, Cancer Res., 52, 101
Kennedy M. J., 1992, Cancer Res., 52, 1278
10.1097/00008390-200004000-00001 · DOI
McBain J. A., 1990, Cell Growth Differ., 1, 281
Jones R. J., 1990, Blood, 75, 1319, 10.1182/blood.V75.6.1319.1319 · DOI
Mohammad R. M., 1994, Cancer Res., 54, 165
Mohammad R. M., 1998, Clin. Cancer Res., 4, 1337
Mohammad R. M., 2000, Clin. Cancer Res., 6, 4950
Beck F. W., 2000, Int. J. Mol. Med., 5, 341
Mohammad R. M., 1999, Int. J. Oncol., 14, 945
Kaubisch A. K.D., 2000, Proc. Am. Soc. Clin. Oncol., 19, 230a
Marshall J. I.J.M., 1998, Proc. Am. Assoc. Cancer Res., 39, 601
Langevin A. M.B.M., 1998, Proc. Am. Soc. Clin. Oncol., 17, 206
Weitman S., 1999, Clin. Cancer Res., 5, 2344
Institute N. C, 1997, Fact Sheet
Grant S., 1998, Clin. Cancer Res., 4, 611
Pavlick A. C.H.A., 2001, Proc. Am. Soc. Clin. Oncol., 20, a328
Bangalore N. S.B.S., 2000, Proc. Am. Soc. Clin. Oncol., 19
Lenz H. J.G.M., 2000, Proc. Am. Soc. Clin. Oncol., 19
Dowlati A. R.K., 2000, Proc. Am. Soc. Clin. Oncol., 19
Grant S. C.L., 2000, Blood, 93, a590
Zonder J. A., 2001, Clin. Cancer Res., 7, 38
Varterasian M. L., 2000, Clin. Cancer Res., 6, 825
Ilson D. S.M., 2001, Proc. Am. Soc. Clin. Oncol., 20, a633,159
Charoentum C. M.A., 2001, Proc. Am. Soc. Clin. Oncol., 20, a2834
Tuttle T. M., 1992, Cancer Res., 52, 548
Tuttle T. M., 1993, Cancer Res., 53, 833

Sorted by citations

Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Marine Natural Products: A Source of Novel Anticancer Drugs
Khalifa, S. A. M., Elias, N., Farag, M. A., Chen, L., Saeed, A., Hegazy, M.-E. F., Moustafa, M. S., Abd El-Wahed, A., Al-Mousawi, S. M., Musharraf, S. G., et al. (2019) · Marine Drugs · doi:10.3390/md17090491 · Cited by 555
PKC Regulates a Farnesyl-Electrostatic Switch on K-Ras that Promotes its Association with Bcl-Xl on Mitochondria and Induces Apoptosis
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467
Tetrahydrofuran-Containing Macrolides: A Fascinating Gift from the Deep Sea
Lorente, A., Lamariano‐Merketegi, J., Alberício, F., & Álvarez, M. (2013) · Chemical Reviews · doi:10.1021/cr3004778 · Cited by 354
Recent advances in deep-sea natural products
Skropeta, D., & Wei, L. (2014) · Natural Product Reports · doi:10.1039/c3np70118b · Cited by 238

See all 185

Authors: Kortmansky, J., & Schwartz, G. K.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
ORCID: Kortmansky, Jeremy
Schwartz, Gary K.
Venue: Cancer Investigation
Publisher: Informa UK Limited
Published: 2003-01
Volume: 21
Issue: 6
Pages: 924-936
ISSN: 0735-7907 (ISSN-L)
1532-4192
DOI: 10.1081/cnv-120025095
OpenAlex: W1996339149
Cited by: 183
References: 109
Citations by year: 2026: 5 · 2025: 10 · 2024: 5 · 2023: 2 · 2022: 8 · 2021: 7 · 2020: 8 · 2019: 6 · 2018: 3 · 2017: 12 · 2016: 9 · 2015: 7 · 2014: 13 · 2013: 4 · 2012: 12
FWCI: 2.07
Type: journal article
Language: en
Open access: closed
Locations: Cancer Investigation (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (R01CA67819, CA09207, R01CA067819, T32CA009207)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Signaling Pathways in Disease
Keywords: bryostatin 1, protein kinase C, PKC inhibitors, macrocyclic lactones, marine natural products, cancer therapy, chemosensitization, apoptosis, cell differentiation, hematologic malignancies, solid tumors, drug toxicity, clinical trials
MeSH terms: Antineoplastic Agents, Cell Differentiation, Humans, Lactones, Nausea, Pain, Protein Kinase C, Vomiting, Down-Regulation, Apoptosis, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Macrolides, Bryostatins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Bryostatin-1: A Novel PKC Inhibitor in Clinical Development

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks